Mubadala Capital has invested $200 million in Tenvie Therapeutics to accelerate its growth in developing innovative treatments for neurological, cardiometabolic, and ophthalmic diseases.
Target Company Overview
Tenvie Therapeutics is a biotechnology company based in San Francisco, launched on January 8, 2025. The firm is committed to developing innovative treatments for neurological, cardiometabolic, and ophthalmic diseases. Tenvie's goal is to significantly alter the treatment paradigm for neurological conditions, aiming to enhance patients' lives through effective therapies.
With a team of specialized experts in neurology, CNS development, small molecule chemistry, and translational medicine, Tenvie is poised to lead advancements in treatments for complex health issues. The company recently secured $200 million in funding to support its mission and expand its clinical capabilities.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biotechnology industry in the United States has been experiencing rapid growth, fueled by advancements in research and development, increased investment, and rising demand for n
Similar Deals
Marlin Equity Partners → Intelligent Locations
2025
Rittenhouse Ventures → S2N Health, Inc.
2025
Mubadala Capital
invested in
Tenvie Therapeutics
in 2025
in a Other VC deal
Disclosed details
Transaction Size: $200M